EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Asciminib, a novel allosteric inhibitor of BCR‐ABL1 , shows synergistic effects when used in combination with imatinib with or without drug resistance

Naoki Okamoto, Kenta Yagi iD, Sayaka Imawaka, Mayu Takaoka, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Koji Miyata, Kei Kawada iD, Yuki Izawa-Ishizawa, Satoshi Sakaguchi, Keisuke Ishizawa

Pharmacology Research & Perspectives · 2024

DOI: 10.1002/prp2.1214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Naoki Okamoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. Hauptthemen laut MEDLINE: Imatinib Mesylate, Fusion Proteins, bcr-abl, Drug Synergism, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to the market as a useful drug for overcoming drug resistance. While combining molecular targeted drugs is useful to avoid drug resistance, the new BCR‐ABL inhibitor asciminib and conventional BCR‐ABL inhibitors should be used as monotherapy in principle. Therefore, we investigated the synergistic effect and mechanism of the combination of asciminib and imatinib. We generated imatinib‐resistant cells using the human CML cell line K562, examined the effects of imatinib and asciminib exposure on cell survival using the WST‐8 assay, and comprehensively analyzed genetic variation related to drug resistance using RNA‐seq and real‐time PCR. A synergistic effect was observed when imatinib and asciminib were combined with or without imatinib resistance. Three genes, GRRP1, ESPN, and NOXA1, were extracted as the sites of action of asciminib. Asciminib in combination with BCR‐ABL inhibitors may improve the therapeutic efficacy of conventional BCR‐ABL inhibitors and prevent the development of resistance. Its dosage may be effective even at minimal doses that do not cause side effects. Further verification of this mechanism of action is needed. Additionally, cross‐resistance between BCR‐ABL inhibitors and asciminib may occur, which needs to be clarified through further validation as soon as possible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateFusion Proteins, bcr-ablDrug SynergismDrug Resistance, NeoplasmLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansK562 CellsProtein Kinase InhibitorsCell SurvivalAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsNiacinamidePyrazoles

Stichwörter der Autor:innen

BCR‐ABL inhibitorsasciminibchronic myelogenous leukemiadrug resistance

Substanzen

Imatinib MesylateasciminibFusion Proteins, bcr-ablBCR-ABL1 fusion protein, humanProtein Kinase InhibitorsAntineoplastic AgentsNiacinamidePyrazoles

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
  • Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.
  • Department of Clinical Pharmacy Practice Pedagogy, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Department of General Medicine, Taoka Hospital, Tokushima, Japan.
  • Department of Respiratory Medicine and Rheumatology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.

ORCID-Profile: Kenta Yagi, Kei Kawada

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Okamoto, N., Yagi, K., Imawaka, S., Takaoka, M., Aizawa, F., Niimura, T., Goda, M., Miyata, K., Kawada, K., Izawa-Ishizawa, Y., Sakaguchi, S., & Ishizawa, K. (2024). Asciminib, a novel allosteric inhibitor of BCR‐ABL1 , shows synergistic effects when used in combination with imatinib with or without drug resistance. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1214

Vancouver

Okamoto N, Yagi K, Imawaka S, Takaoka M, Aizawa F, Niimura T, et al. Asciminib, a novel allosteric inhibitor of BCR‐ABL1 , shows synergistic effects when used in combination with imatinib with or without drug resistance. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.1214

BibTeX
@article{Okamoto2024,
  author = {Okamoto, Naoki and Yagi, Kenta and Imawaka, Sayaka and Takaoka, Mayu and Aizawa, Fuka and Niimura, Takahiro and Goda, Mitsuhiro and Miyata, Koji and Kawada, Kei and Izawa-Ishizawa, Yuki and Sakaguchi, Satoshi and Ishizawa, Keisuke},
  title = {Asciminib, a novel allosteric inhibitor of BCR‐ABL1 , shows synergistic effects when used in combination with imatinib with or without drug resistance},
  journal = {Pharmacology Research & Perspectives},
  year = {2024},
  doi = {10.1002/prp2.1214}
}
Kostenlos starten →